Innovative device technology
Our flagship product, Apollo (PITO-001; personalized injection treatment optimizer) is a first of its kind smart desktop compounding device. In 2017, we received patents in US, Europe and Korea for the technologies. As one of the output form factors, we developed AQT series, world’s first microchannel mesotherapy® device™ and secured related IP and Trademarks. Because of its unique positioning and market demand, we are pursuing a clear regulatory pathway for AQT-004 and iMicrotox™ (AQB-121) for FDA approval. iMicrotox™, with its unique periorbital application capability, is forecasted to capture at least 10-20% of the current global botulinum toxin market. In addition, AQUABELO™ (Microfill HA™) compliments and expands our market with its free standing innovation.
DTX-021 is a botulinum toxin that is an injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum, the bacterium responsible for botulism. Through the inhibition of neurotransmission between peripheral nerve endings and muscle fibers, the botulinum toxin weakens or paralyzes skeletal muscle. DTX-021 has shown equivalency to onabotulinumtoxinA (BOTOX®) on treating glabellar lines and improvement on periorbital rhytids.
One of Aquavit’s commercial products, based on the microchannel technology® - AQUAGOLD® - has been empowering our physicians to personalize treatment choices and modernize their therapeutic approaches. Medical professionals are using AQUAGOLD® to deliver agents to address skin conditions using drugs of their choice, achieving both ultimate patient's satisfaction and desired results.
MICROTOX™ & MICROFILL™
As the next phase, Aquavit will be introducing very soon MICROTOX™ and MICROFILL™ that deliver neuromodulators and hyaluronic acid fillers interdermally, respectively, using our AQT-004 delivery technology.
The first of its kind, smart desktop compounding technology (PITO-001/QVT series) with AI integration and a big data platform (MAV series).